SCHEMBL24314020

SCHEMBL24314020

CC(=O)Oc1cccc(-c2ccc3c(c2)CCC(=O)N3)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.55
CYP11B2 P19099 3/20 0.55
CYP1A2 P05177 2/20 0.55
PDE3B Q13370 2/20 0.53
PDE3A Q14432 2/20 0.53
CYP2C9 P11712 2/20 0.53
TBXAS1 P24557 1/20 0.53
KIF11 P52732 3/20 0.50
MAPT P10636 3/20 0.44
NPC1 O15118 1/20 0.44
MMP12 P39900 1/20 0.44
RAB9A P51151 1/20 0.44
PKM P14618 1/20 0.44
PGR P06401 1/20 0.44
CRBN Q96SW2 3/20 0.44
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2B6 P20813 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24314052 0.89 CYP11B1 (0.52) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL27485474 0.85 MAOA (0.53) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL24314993 0.84 CYP1A2 (0.70) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL3309000 0.81 TDP2 (0.60) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL24314011 0.80 FABP7 (0.48) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL3468129 0.79 KIF11 (0.69) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL26793370 0.78 FABP7 (0.56) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL24314079 0.78 FABP7 (0.74) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL29532812 0.78 FABP7 (0.74) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL24314085 0.78 FABP7 (0.74) CYP11B1CYP11B2CYP1A2PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365488-A1 TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-11-16 US disclosed
WO-2022076820-A1 TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365488-A1 TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FABP5, FABP1, FABP4 CYP11B1 3052/4885CYP11B2 3035/4885CYP1A2 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.